Yang Xue-Jing, Song Dong, Yang Xiao-Ling, Guo Xin
Cancer Center, Shanxi Academy of Medical Science/Shanxi Bethune Hospital, Taiyuan 030032, Taiyuan, Shanxi, China.
Summary
Purpose: To investigate the safety and efficacy of low-dose apatinib combined with chemotherapy in the second-line treatment of advanced gastric cancer.
Methods: After retrospectively analyzing the clinical data of 96 patients with advanced gastric cancer admitted to the cancer center of Shanxi Bethune hospital from January 2016 to January 2020, and after progression to first-line chemotherapy, we used low-dose apatinib (250mg and 500mg respectively) combined with chemotherapy as second-line treatment. Compared with simultaneous simple chemotherapy, we analyzed the objective effective rate (ORR), disease control rate (DCR), progression-free survival (PFS) as well as overall survival (OS) of the combination treatment to evaluate the effect and related adverse reactions.
Results: Among the 96 patients, the most common adverse reactions were hypertension, hand-foot skin reaction and proteinuria in the targeted combined chemotherapy group. The ORR and DCR values of the targeted combined chemotherapy group were higher. The mPFS of 250 and 500 mg combined chemotherapy group and chemotherapy-alone were 5.8, 6.1 and 4.3 months, mOS were 7.2, 7.5 and 6.7 months, respectively. The results showed that mPFS and mOS of apatinib combined with chemotherapy were significantly better than that of chemotherapy with statistical significance.
Conclusion: Second-line chemotherapy in the treatment of advanced gastric cancer, with low dose of apatinib combined with chemotherapy not only offers good survival benefits, but does not increase the drug-related adverse reactions comparing with the simple chemotherapy group.
Key words: apatinib; advanced gastric cancer; low dose; adverse event.
Full Text: PDF